As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is a 2-year smart reusable pen injector sensor compatible with the majority of insulin injectable pens, both disposable and reusable. It automatically collects the dose of insulin delivered with an accuracy close to 100%.
In the future, Mallya will also be part of the RocheDiabetes ecosystem of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patient care.
Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of the portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of the glycemic results.
Thanks to Mallya, the patient will no longer have to manually declare the doses of insulin injected in the future because, once the sensor is coupled to the Gluci-Chek application, the data will be automatically reported and displayed in the monitoring log. blood sugar regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The signing of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates our readers’ blood glucose data via Gluci-Chek and automatic insulin data via Mallya. ”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients in its commercial offer. I would like to thank the Roche Diabetes Care France teams for their responsiveness over the past few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders at the start of 2020 on the diabetes digitization market and the considerable commercial potential of Mallya. With a partner of Roche’s caliber, we are convinced that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake. ”
ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For over 40 years, it has designed solutions that meet the needs of patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and educational support) and digital solutions (applications, platform sharing blood sugar data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care opens the way to personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, visit www.roche.fr.
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has now acquired a leading position in the market for connected medical devices thanks to Mallya. This intelligent sensor for insulin injector pens allows reliable monitoring of injected doses and thus provides better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads the BIOCORP product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP has been listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on twitter @BIOCORPSystems
1 SoloStar by Sanofi – KwikPen by Eli Lilly – FlexPen by Novo Nordisk